Agilent Technologies CEO Padraig McDonnell Highlights Strong Q2 FY26 Performance as Company Raises Full-Year Revenue and EPS Guidance

29 May 2026 | Friday | Company results

Agilent reports 10% second-quarter revenue growth to $1.83 billion, expands non-GAAP operating margin to 26.4%, and boosts FY26 outlook amid strong operational execution, innovation momentum, and broad-based market demand.

Delivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS⁽⁴⁾ guidance on continued operational momentum

Second-quarter fiscal year 2026

Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core⁽¹⁾ compared with the second quarter of 2025.
GAAP operating margin of 21.7%; non-GAAP operating margin⁽²⁾ of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially.
GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025.
Non-GAAP net income⁽³⁾ of $423 million; non-GAAP EPS⁽³⁾ of $1.49, an increase of 14% from the second quarter of 2025.

Fiscal year 2026 improved outlook and third-quarter guidance

Fiscal year 2026 revenue is now expected in the range of $7.39 billion to $7.49 billion, representing a range of up 6.3% to 7.8% reported and up 4.5% to 6.0% core,⁽¹⁾⁽⁵⁾ an increase of 30 basis points at the midpoint. Non-GAAP fiscal year 2026 operating margin expansion⁽²⁾ at the midpoint of core revenue growth guidance is now expected to be 85 basis points, an increase of 10 basis points. Non-GAAP EPS⁽⁴⁾ is now expected in the range of $6.00 to $6.10, an increase of 8 cents at the midpoint.
Fiscal third-quarter 2026 revenue is expected in the range of $1.83 billion to $1.85 billion, growth of 5.0% to 6.5% reported and up 4.4% to 5.9% core⁽¹⁾⁽⁵⁾. Non-GAAP EPS⁽⁴⁾ is expected in the range of $1.48 to $1.50 per share.

Agilent Technologies Inc. reported revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core⁽¹⁾ compared with the second quarter of 2025.

Second-quarter GAAP net income was $339 million, or $1.20 per share. This compares with $215 million, or $0.75 per share, in the second quarter of 2025. Non-GAAP net income was $423 million, or $1.49 per share, during the quarter, compared with $373 million, or $1.31 per share, during the year-ago quarter.

“It was an excellent second quarter for Agilent, with broad-based strength across key end markets, exceptional operational execution and strong margin performance,” said Padraig McDonnell, president and CEO of Agilent Technologies. “The continued momentum we are seeing across the business reflects the strength of our customer-focused strategy, healthy underlying demand, and the increasing impact of the Ignite Operating System across the organization, supported by the resilience of our diversified portfolio. Innovation remains a key driver of our long-term growth. The introduction of solutions such as our new 9500 ICP-MS platform demonstrates our ability to anticipate evolving customer needs and translate those insights into differentiated technologies that improve laboratory productivity and performance. Combined with the continued progress of Ignite, replacement-cycle momentum, and a strong innovation pipeline, we remain well positioned to deliver sustainable growth and long-term value for our customers and shareholders.”

Financial Highlights

Life Sciences and Diagnostics Markets Group

The Life Sciences and Diagnostics Markets Group (LDG) reported second-quarter revenue of $732 million, growth of 12% reported and 9% core⁽¹⁾ year-over-year. LDG’s operating margin for the quarter was 22.0%.

Agilent CrossLab Group

The Agilent CrossLab Group (ACG) reported second-quarter revenue of $759 million, growth of 6% reported and 2% core⁽¹⁾ year-over-year. ACG’s operating margin for the quarter was 32.0%.

Applied Markets Group

The Applied Markets Group (AMG) reported second-quarter revenue of $344 million, growth of 14% reported and 11% core⁽¹⁾ year-over-year. AMG’s operating margin for the quarter was 23.3%.

Partner Content

BioPharma BreakThrough's

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

Gene Editing Breakthroughs

Innovative Drug Discovery

Vaccine Development

Biologics and Therapeutic Antibodies

× Please select an option to participate in the poll.

View poll results More polls

× You have successfully cast your vote.

{{ optionDetail.option }} {{ optionDetail.percentage }}%

More polls

Agilent Technologies CEO Padraig McDonnell Highlights Strong Q2 FY26 Performance as Company Raises Full-Year Revenue and EPS Guidance